NCT07020065 2026-04-15
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Swiss Cancer Institute
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06632327 2026-04-07
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT03158129 2026-04-06
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05624996 2026-04-03
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Phase 3 Recruiting
NCT07001618 2026-04-03
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT06745882 2026-04-02
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06812871 2026-04-02
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
Phase 2 Completed
NCT05254184 2026-03-30
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT06538038 2026-03-27
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Recruiting
NCT04253964 2026-03-19
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Wake Forest University Health Sciences
Phase 2 Recruiting